Valuation: Evotec

Market Cap 872M 993M 804M 752M 1.41B 93.64B 1.44B 9.67B 3.74B 46.22B 3.73B 3.65B 161B P/E 2026 *
-6.9x
P/E 2027 * -25.1x
Enterprise Value 886M 1.01B 817M 764M 1.43B 95.18B 1.46B 9.83B 3.8B 46.97B 3.79B 3.71B 163B EV / Sales 2026 *
1.2x
EV / Sales 2027 * 1.15x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 43 22/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
+8.33%-.--% - - 979M
-0.48%+8.75%-5.51%+0.91% 46.36B
+2.19%+11.71%+374.04%+613.48% 37.88B
+2.53%+13.93%+20.43%-10.71% 31.12B
+1.65%+3.61%+4.78%+56.12% 30.61B
-4.16%-4.44%+8.53%+16.06% 24.69B
-0.32%+12.96% - - 16.25B
+1.37%+14.53%+69.40%+135.94% 14.85B
+1.00%+9.67%+14.90%+21.88% 13.58B
+3.63%+9.53%+102.95%+104.79% 12.95B
Average +1.57%+7.85%+73.69%+117.31% 25.36B
Weighted average by Cap. +0.75%+7.66%+82.40%+135.51%

Financials

2026 *2027 *
Net sales 738M 840M 680M 636M 1.19B 79.21B 1.22B 8.18B 3.16B 39.09B 3.15B 3.08B 136B 818M 931M 754M 705M 1.32B 87.82B 1.35B 9.07B 3.51B 43.34B 3.5B 3.42B 151B
Net income -113M -129M -104M -97.66M -183M -12.16B -187M -1.26B -486M -6B -484M -473M -20.85B -30.42M -34.63M -28.04M -26.24M -49.14M -3.27B -50.19M -337M -130M -1.61B -130M -127M -5.6B
Net Debt 14.3M 16.28M 13.18M 12.33M 23.1M 1.54B 23.59M 159M 61.32M 758M 61.12M 59.78M 2.63B 69.32M 78.91M 63.89M 59.79M 112M 7.44B 114M 769M 297M 3.67B 296M 290M 12.77B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
4.906EUR
Average target price
6.443EUR
Spread / Average Target
+31.33%

Quarterly revenue - Rate of surprise